Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push
On Wednesday, 09 September 2026, Mirum Pharmaceuticals (MIRM) participated in the 12th Annual Cantor Fitzgerald Global Healthcare Conference to unveil a strategy centered around rare-disease growth. Chief Executive Chris Peetz emphasized the company's focus on acquiring overlooked medicines, with three approved products generating annualized revenue between $680 million and $700 million.
The company anticipates a pivotal moment as late-stage readouts and potential approvals roll in through 2025 and beyond. Mirum prefers buying and developing rare-disease assets over competing in large mainstream drug markets. LIVMARLI, the main growth driver, is projected to reach sales above $1 billion, with potential upside if new data supports broader use.
Volixibat, used in primary sclerosing cholangitis, faces a more complicated FDA approval process, even after receiving Breakthrough Therapy Designation. The company expects several key events in the coming quarters, including Phase III readouts for LIVMARLI, brelovitug, and volixibat, as well as a PDUFA decision for zilurgisertib.
Mirum maintains substantial liquid assets, with a current ratio of 2.86, indicating no immediate financing needs. The company's mission is centered on discovering rare diseases that have been overlooked, bringing them into a focused platform to develop high-impact medicines.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
